GLPwatch
Semaglutide Treatment On Coronary Progression
NCT03985384 · Completed
Last updated 2026-05-28This clinical trial is testing whether the medication semaglutide can slow the buildup of fatty deposits in the heart’s arteries in adults with type 2 diabetes and coronary artery disease.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 140 people
Who can join Ages 40+ · all sexes
Timeline Started 2019-04 · est. completion 2022-12
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT03985384 ↗
Description as written by the study sponsor.
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.
Treatments tested
- Semaglutide 2 MG/1.5 ML Subcutaneous Solution Drug
Semaglutide 2 MG/1.5 ML Subcutaneous Solution
- Placebo Drug
Placebo 1.5 ml, pen-injector for SC injection.
| Main thing measured | Rate of change in non-calcified plaque volume |
|---|---|
| Sponsor | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center |
| Conditions studied | Type 2 Diabetes, Coronary Artery Disease |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03985384 ↗